Concierge Medicine 2.0 by Castle Connolly Private Health Partners
Business of Cardiology
Implementing the Topcon Ocular Telehealth Platform
Legal and Policy
Linagliptin cardiovascular safety profile appears superior to glimepiride
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.